- In February 2024, HemoCue has partnered with Novo Nordisk to enhance point-of-care diagnostic testing for children with type 1 diabetes in low- and middle-income countries. The collaboration will deploy HemoCue HbA1c 501 Systems across 30 countries, aiming to improve diabetes management and reach 100,000 children by 2030
- In January 2024, Roche announced the acquisition of LumiraDx's point-of-care testing technology for USD 295 million, with an additional investment of up to USD 55 million to support Lumira's technology platform until the deal is finalized
- In April 2023, FIND partnered with Abbott, i-SENS Inc., and Siemens Healthineers to provide discounted point-of-care HbA1c test kits for low- and middle-income countries, focusing on improving diabetes diagnosis and management in underserved regions
- In November 2022, LumiraDx expanded the commercial reach of its HbA1c test, aiming to address diabetes management needs in various care settings. The test, run on the LumiraDx Platform, offers rapid results to support screening and monitoring, potentially improving patient outcomes
- In May 2022, Labcorp introduced an at-home collection kit for diabetes risk testing using a new device from Weavr Health. This initiative provides convenience and accessibility, enabling individuals to monitor their health status from home
